Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
INCY
Strong BuyAPPROVEIncyte Corporation · Healthcare · United States · $25.2B · Avg Vol: $202M/d
Incyte generates large cash flow from Jakafi and a growing dermatology franchise, runs a net-cash balance sheet and has been executing sizeable share repurchases, which is consistent with its strong quality score (Q86) and firm momentum. The trivial insider selling reads as routine plan activity. No accounting, distress or governance issue is known.
COMPANY DESCRIPTION
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, primarily in oncology and inflammation/autoimmunity. The company possesses a robust pipeline of innovative small-molecule drugs and a flagship product, Jakafi, which holds a leading market position in myelofibrosis and polycythemia vera. It is a leading biopharmaceutical innovator, recognized for its contributions to oncology and inflammatory disease treatments.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.4B | 3.7B | 4.2B | 5.1B | 14.8% | 5.8B | 5.9B | 6.3B | 10.4% |
| EPS | 1.53 | 2.67 | 0.16 | 6.59 | 62.7% | 7.85 | 3.37 | 8.66 | 14.7% |
| Shares | 222.7M | 224.3M | 193.4M | 198.5M | -10.9% | 202.7M | — | — | — |
| Debt | 41.5M | 38.3M | 43.5M | 40.4M | -0.8% | 38.3M | — | — | — |
| Equity | 4.4B | 5.2B | 3.4B | 5.2B | 5.7% | — | — | — | — |
| Op CF | 969.9M | 496.5M | 335.3M | 1.4B | 13.4% | 2.0B | — | — | — |
| Inv CF | -78.5M | -207.7M | 157.5M | -102.6M | — | — | — | — | — |
| Fin CF | -0.8M | -20.0M | -2.0B | 101.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INCY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INCY | Incyte Corporation(you) | $25.2B | 96 | Strong Buy |
| EXEL | Exelixis, Inc. | $13.5B | 99 | Strong Buy |
| HALO | Halozyme Therapeutics, Inc. | $12.0B | 95 | Strong Buy |
| CORT | Corcept Therapeutics Incorporated | $12.3B | 80 | Buy |
| REGN | Regeneron Pharmaceuticals, Inc. | $81.8B | 85 | Strong Buy |
| VRTX.MX | Vertex Pharmaceuticals Incorporated | $140.6B | 94 | Strong Buy |
| TECH | Bio-Techne Corporation | $11.3B | 74 | Buy |
| RPRX | Royalty Pharma plc | $35.2B | 64 | Hold |
| KRYS | Krystal Biotech, Inc. | $10.4B | 73 | Buy |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.0B | 81 | Strong Buy |
Peer medians: ROE -25.9% · P/E 29.6x · Gross margin 58.8%